CONNECT WITH US
HealthTech

HealthTech

Melanoma protein patterns help predict immunotherapy response, survival

Medical Xpress logo

Published on

Add as a preferred source on Google
Melanoma protein patterns help predict immunotherapy response, survival

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

Protein patterns in melanoma tumors can predict how patients respond to immunotherapy and can be used to find promising biomarkers and drug targets, according to two new University of Pittsburgh studies.

The companion studies, published in Cancer Discovery and Clinical Cancer Research, developed a molecular atlas of melanoma and a method of classifying and predicting immunotherapy response based on protein patterns. Determining which patients are most likely to respond to immunotherapy before treatment begins may allow patients who are unlikely to benefit to avoid harmful side effects and prevent delays in starting better treatment options.

Immune checkpoint inhibitors, a type of cancer immunotherapy, have dramatically improved melanoma patient survival in the last 15 years. But a large percentage of patients don't respond to the treatment, and biomarkers that predict treatment response remain elusive. To better understand why some patients are resistant to the treatment, researchers looked to the proteome, the entire set of proteins expressed in a tissue or organism.

"In 2003, we decoded the human genome. , associate professor of medicine at Pitt and co-leader of the Cancer Immunology and Immunotherapy Program at UPMC Hillman Cancer Center.



Source link

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.